Chronic GvHD in a prognostic model: Graft versus leukemia predictor or immortal time bias? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37713530/
Chronic GvHD in a prognostic model: Graft versus leukemia predictor or immortal time bias?
Relevance: Zhou et al. recently published a prognostic model for patients with chronic myelomonocytic leukemia (CMML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT) in this journal. This score consisted of five items: Age, Blasts, Leukocytes, Anemia, and chronic Graft vs Host Disease (ABLAG). The strongest predictor in...
Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36800551/
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management...
Conclusions/Relevance: Currently, ibrutinib, ruxolitinib, and belumosudil are the only drugs that are approved by the Food and Drug Administration for steroid-refractory cGVHD. In light of the current standard management of cGVHD, the trial results indicate that ibrutinib will remain reserved for second-line therapy, which may be due to its...
Comparative transcriptome profile of mouse macrophages treated with the RhoA/Rock pathway inhibitors Y27632, Fingolimod (Gilenya), and Rezurock (Belumosudil, SLx-2119)
Source : https://www.sciencedirect.com/science/article/abs/pii/S1567576923003387?via=ihub
Macrophages play a crucial role in, the currently uncurable, chronic rejection of transplants. In rodent transplantation models, inhibition of the Rho...
Conclusions/Relevance: The result of this study not only uncovers which pathways are shared or specific for these drugs but will help in the development of macrophage pathway-targeted therapies in human transplantation, MS, and GVHD. Because macrophages are the major players in immune response, tissue regeneration, renewal, and homeostasis,...
Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-versus-Host Disease
Source : https://www.sciencedirect.com/science/article/abs/pii/S2666636723013593?via=ihub
Belumosudil (BEL) is a novel Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor approved for the treatment of chronic graft-vers...
Conclusions/Relevance: We recommend empiric dose reductions of 25% for tacrolimus and 25% to 50% for sirolimus when adding BEL, as well as close monitoring of IS levels during the initial weeks of BEL therapy. Future studies are warranted to better describe the impact of BEL on patients taking CYP3A inhibitors.
Updates in chronic graft-versus-host disease management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37483142/
Chronic graft-versus-host disease (cGvHD) remains the most important long-term complication of allogeneic hematopoietic cell transplantation (allo-HCT), but the field has seen significant changes in the last decade. Remarkable advances in...
Conclusions/Relevance: Remarkable advances in the understanding of the biological pathways of cGvHD, lead to the development of targeted therapy with novel drugs thereby minimizing the exposure to harmful corticosteroids, preserving function and mobility, preventing disability, and improving quality of life (QoL) and overall survival (OS)....